Literature DB >> 21785431

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.

Timothy Best1, Dalin Li, Andrew D Skol, Tomas Kirchhoff, Sarah A Jackson, Yutaka Yasui, Smita Bhatia, Louise C Strong, Susan M Domchek, Katherine L Nathanson, Olufunmilayo I Olopade, R Stephanie Huang, Thomas M Mack, David V Conti, Kenneth Offit, Wendy Cozen, Leslie L Robison, Kenan Onel.   

Abstract

Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21785431      PMCID： PMC3229923          DOI： 10.1038/nm.2407

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  20 in total

1.  Genomic control for association studies.

Authors:  B Devlin; K Roeder
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

Review 2.  Gene--environment-wide association studies: emerging approaches.

Authors:  Duncan Thomas
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

3.  Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease.

Authors:  C Behrens; L B Travis; I I Wistuba; S Davis; A Maitra; E A Clarke; C F Lynch; B Glimelius; T Wiklund; R Tarone; A F Gazdar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-10       Impact factor: 4.254

4.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.

Authors:  Jonathan Mandelbaum; Govind Bhagat; Hongyan Tang; Tongwei Mo; Manisha Brahmachary; Qiong Shen; Amy Chadburn; Klaus Rajewsky; Alexander Tarakhovsky; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

5.  Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.

Authors:  Dinis Pedro Calado; Baochun Zhang; Lakshmi Srinivasan; Yoshiteru Sasaki; Jane Seagal; Christine Unitt; Scott Rodig; Jeffery Kutok; Alexander Tarakhovsky; Marc Schmidt-Supprian; Klaus Rajewsky
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

6.  Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation.

Authors:  Y Lin; K Wong; K Calame
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

7.  A map of human genome variation from population-scale sequencing.

Authors:  Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

8.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Authors:  Lois B Travis; Deirdre A Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Tom Wiklund; Charles F Lynch; Mars B Van't Veer; Ingrid Glimelius; Hans Storm; Eero Pukkala; Marilyn Stovall; Rochelle Curtis; John D Boice; Ethel Gilbert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.

Authors:  J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 11.816

10.  Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.

Authors:  Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia
Journal:  J Natl Cancer Inst       Date:  2010-07-15       Impact factor: 11.816
View more
  66 in total

1.  Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.

Authors:  Lindsay M Morton; Luisel Ricks-Santi; Catharine M L West; Barry S Rosenstein
Journal:  Int J Part Ther       Date:  2018-09-21

Review 2.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

Review 3.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

4.  A step toward slaying the hydra of second cancers.

Authors:  Lindsay M Morton; Stephen J Chanock
Journal:  Nat Med       Date:  2011-08-04       Impact factor: 53.440

5.  Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

6.  Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence.

Authors:  Wolfgang Dörffel; Marianne Riepenhausenl; Heike Lüders; Jürgen Brämswig; Günther Schellong
Journal:  Dtsch Arztebl Int       Date:  2015-05-01       Impact factor: 5.594

7.  Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.

Authors:  Min Yi; Janice N Cormier; Yan Xing; Sharon Hermes Giordano; Christy Chai; Funda Meric-Bernstam; Georges Vlastos; Henry M Kuerer; Nadeem Q Mirza; Thomas A Buchholz; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2012-12-06       Impact factor: 5.344

Review 8.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

9.  Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Authors:  Grace Choi; Brian Huang; Emile Pinarbasi; Steve E Braunstein; Andrew E Horvai; Scott Kogan; Smita Bhatia; Bruce Faddegon; Jean L Nakamura
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

10.  Radiogenomics: radiobiology enters the era of big data and team science.

Authors:  Barry S Rosenstein; Catharine M West; Søren M Bentzen; Jan Alsner; Christian Nicolaj Andreassen; David Azria; Gillian C Barnett; Michael Baumann; Neil Burnet; Jenny Chang-Claude; Eric Y Chuang; Charlotte E Coles; Andre Dekker; Kim De Ruyck; Dirk De Ruysscher; Karen Drumea; Alison M Dunning; Douglas Easton; Rosalind Eeles; Laura Fachal; Sara Gutiérrez-Enríquez; Karin Haustermans; Luis Alberto Henríquez-Hernández; Takashi Imai; George D D Jones; Sarah L Kerns; Zhongxing Liao; Kenan Onel; Harry Ostrer; Matthew Parliament; Paul D P Pharoah; Timothy R Rebbeck; Christopher J Talbot; Hubert Thierens; Ana Vega; John S Witte; Philip Wong; Frederic Zenhausern
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.